Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655299 | 0.79 | MAPT (0.66) | MAPTTDP1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL8923934 | 0.78 | CHRNB2 (0.56) | MAPTTDP1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL8155209 | 0.76 | MAPT (0.61) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL2082827 | 0.76 | MAPT (1.00) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL10896316 | 0.76 | MAPT (1.00) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| SCHEMBL2084131 | 0.76 | MAPT (0.66) | MAPTTDP1SMN1; SMN2ALDH1A1ERN1 | |
| Formamide SCHEMBL9819793 | 0.73 | CHRNB2 (0.46) | MAPTTDP1SMN1; SMN2ALDH1A1CYP1A2 | |
| Bicarbonate SCHEMBL9826841 | 0.73 | MAPT (0.58) | MAPTTDP1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL2084173 | 0.73 | MAPT (0.62) | MAPTTDP1SMN1; SMN2ALDH1A1MAOA | |
| SCHEMBL2083948 | 0.72 | MAPT (0.56) | MAPTTDP1SMN1; SMN2ALDH1A1NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1583757-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
| CN-1058780-A | Has the active thiazolidine carboxylic acid amides derivative of anti-allergy, their preparation and application | SANKYO CO (JP) | 1992-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | MAPT 2537/4885TDP1 235/4885SMN1; SMN2 1424/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | MAPT 2917/4885TDP1 611/4885SMN1; SMN2 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.